Equities analysts expect BioLife Solutions Inc (NASDAQ:BLFS) to report earnings of $0.04 per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for BioLife Solutions’ earnings, with the highest EPS estimate coming in at $0.05 and the lowest estimate coming in at $0.04. BioLife Solutions reported earnings of ($0.05) per share during the same quarter last year, which would indicate a positive year over year growth rate of 180%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 14th.
According to Zacks, analysts expect that BioLife Solutions will report full-year earnings of $0.15 per share for the current financial year, with EPS estimates ranging from $0.14 to $0.16. For the next year, analysts anticipate that the company will report earnings of $0.26 per share, with EPS estimates ranging from $0.23 to $0.32. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow BioLife Solutions.
BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, November 8th. The medical equipment provider reported $0.05 EPS for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.01. The business had revenue of $5.29 million for the quarter, compared to analysts’ expectations of $5.19 million. BioLife Solutions had a return on equity of 8.63% and a net margin of 10.42%.
Several equities analysts have recently issued reports on BLFS shares. Janney Montgomery Scott raised BioLife Solutions to a “buy” rating and set a $5.00 target price on the stock in a research note on Thursday, December 20th. ValuEngine raised BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Thursday, January 31st. Finally, B. Riley set a $22.00 target price on BioLife Solutions and gave the company a “buy” rating in a research note on Friday, November 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $17.75.
BLFS opened at $16.06 on Wednesday. BioLife Solutions has a 52-week low of $4.72 and a 52-week high of $26.35. The company has a market cap of $297.11 million, a PE ratio of -76.48 and a beta of 1.49.
In other BioLife Solutions news, CEO Michael Rice sold 14,781 shares of the business’s stock in a transaction on Thursday, December 13th. The stock was sold at an average price of $11.44, for a total value of $169,094.64. Following the sale, the chief executive officer now directly owns 154,298 shares of the company’s stock, valued at $1,765,169.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrew G. Hinson sold 4,000 shares of the business’s stock in a transaction on Thursday, December 13th. The stock was sold at an average price of $12.05, for a total value of $48,200.00. Following the completion of the sale, the director now directly owns 45,747 shares in the company, valued at $551,251.35. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,562 shares of company stock worth $664,696. 38.50% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in BLFS. Canton Hathaway LLC bought a new stake in BioLife Solutions in the fourth quarter worth $66,000. Jane Street Group LLC bought a new position in shares of BioLife Solutions during the second quarter valued at $173,000. Northern Trust Corp lifted its holdings in shares of BioLife Solutions by 24.4% during the second quarter. Northern Trust Corp now owns 16,304 shares of the medical equipment provider’s stock valued at $186,000 after purchasing an additional 3,200 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of BioLife Solutions during the third quarter valued at $200,000. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of BioLife Solutions by 7.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 20,515 shares of the medical equipment provider’s stock valued at $247,000 after purchasing an additional 1,400 shares in the last quarter. 41.06% of the stock is currently owned by institutional investors and hedge funds.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
Further Reading: Understanding the different types of bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.